Literature DB >> 29167811

Datasets, processing and refinement details for Mtb-AnPRT: inhibitor structures with various space groups.

Genevieve L Evans1, Daniel P Furkert2, Nacim Abermil2, Preeti Kundu3, Katrina M de Lange1, Emily J Parker3, Margaret A Brimble2, Edward N Baker1, J Shaun Lott1.   

Abstract

There are twenty-five published structures of Mycobacterium tuberculosis anthranilate phosphoribosyltransferase (Mtb-AnPRT) that use the same crystallization protocol. The structures include protein complexed with natural and alternative substrates, protein:inhibitor complexes, and variants with mutations of substrate-binding residues. Amongst these are varying space groups (i.e. P21, C2, P21212, P212121). This article outlines experimental details for 3 additional Mtb-AnPRT:inhibitor structures. For one protein:inhibitor complex, two datasets are presented - one generated by crystallization of protein in the presence of the inhibitor and another where a protein crystal was soaked with the inhibitor. Automatic and manual processing of these datasets indicated the same space group for both datasets and thus indicate that the space group differences between structures of Mtb-AnPRT:ligand complexes are not related to the method used to introduce the ligand.

Entities:  

Keywords:  Crystallography; Ligand binding; Macromolecules; Structure-based inhibitor design; X-ray diffraction

Year:  2017        PMID: 29167811      PMCID: PMC5686470          DOI: 10.1016/j.dib.2017.10.051

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the data Mtb-AnPRT is a target of interest in developing novel anti-tuberculosis agents. This protein's capacity to crystallize thus yield new protein:ligand complexes makes it of interest for structure-based inhibitor design. Previously Mtb-AnPRT:ligand complexes have been found with different space groups (e.g. P21, C2, P21212, and P212121), generated by using the same crystallization protocol. Mtb-AnPRT:inhibitor complex structures described herein have C2 and P21 space groups. These structures were solved using X-ray diffraction datasets from protein:ligand crystals generated by streak-seeded with wild-type P212121 crystal. For one inhibitor, X-ray diffraction datasets are presented for both co-crystallization and soaked crystal experiments. Space group C2 occurred in both datasets and indicates the space group change between ligand-free and inhibitor-bound structures are independent of method used to introduce the inhibitor. X-ray diffraction datasets utilizing different methods of ligand introduction and yielding equivalent protein:ligand structures are typically not made available. These publically available datasets in the context of multiple space groups observed for Mtb-AnPRT:ligand structures, and the analysis presented herein, demonstrate that space group changes can be independent of co-crystallization and soaking methods of ligand introduction. This has relevance to academic and industrial researchers who are pursuing structure-based inhibitor design.

Data

Overview

The experimental and data processing details for 3 new protein:ligand structures of Mycobacterium tuberculosis anthranilate phosphoribosyl transferase (Mtb-AnPRT) are described herein (Table 1). The protein structures are complexed with Mtb-AnPRT inhibitors characterized in [1] and annotated as:
Table 1

Summary of Mtb-AnPRT structures described herein.

PDB IDLigand IDSolvent contentUnit Cell
Space groupResolution (Å)ChainsPDB DOI
β (°)A (Å)B (Å)C (Å)
5BO28i46%111°9478103C22.00A,B10.2210/pdb5bo2/pdb
5BO38j46%111°9578103C21.75A,B10.2210/pdb5bo3/pdb
5BNE8k46%91°7778117P212.15A,B,C D10.2210/pdb5bne/pdb
8k (2-(2-carboxyphenylamino)-5-(5-phosphonopentyloxy)benzoic acid) 8j (2-(2-carboxyphenylamino)-5-(4-phosphonobutoxy)benzoic acid) 8i (2-(2-carboxyphenylamino)-5-(3-phosphonopropoxy)benzoic acid) Summary of Mtb-AnPRT structures described herein. These structures were determined with protein crystallized in presence of imidazole-malate and PEG4000. Crystallization drops seeded with crystal nuclei from a pre-existing Mtb-AnPRT crystal generate better crystal morphology for Mtb-AnPRT [2]. All new structures presented herein were generated by streak-seeding using wild-type P212121 crystals. Also presented are two X-ray diffraction datasets corresponding to protein crystals either soaked and co-crystallized with the same inhibitor (Table 2).
Table 2

Crystallization of complexes, along with space group and unit cell from data processing.

PDB IDLigand(s) bound[Protein] mg mL1Reservoir conditionCryoprotectant/SoakNotesSpace groupUnit cell
5BO28i :3.00.2 M imidazole.malate, pH 7.0, 9% PEG40000.2 M imidazole.malate, pH 7.0, 15% PEG4000, 1 mM 8iStreak seeded; soaked crystal for 4 h;C294×78×103 Å
Image 12 day old crystal
X-ray images available at:http://dx.doi.org/10.17632/xgn5z8jnr7.1ßβ=111°
Not applicable8i :3.00.2 M imidazole.malate, pH 7.0, 11% PEG4000, 1 mM 8i0.2 M imidazole.malate, pH 7.0, 15% PEG4000, 1 mM 8iStreak seeded; protein co-crystallized with ligand;C295×78×103 Å
Image 22 day old crystal
β=111°
X-ray images available at:http://dx.doi.org/10.17632/2zrfgv34nb.1
5BO38j :3.00.2 M imidazole.malate, pH 7.0, 11% PEG4000,0.2 M imidazole.malate, pH 7.0, 15% PEG4000, 1 mM 8jStreak seeded; soaked crystal for 10 min;C295×78×103 Å
Image 3
2 day old crystal
β=111°
5BNE8k :3.10.2 M imidazole.malate, pH 7.0, 15% PEG4000, 1 mM 8kNo cryo used, because crystallization condition contained 15% PEG4000Streak seeded; protein co-crystallized with ligand;P2177×78×117 Å
Image 4
2 day old crystal
β=91°
Crystallization of complexes, along with space group and unit cell from data processing. Of the previously published structures of Mtb-AnPRT, 25 were determined from protein crystallized using this protocol (Table 3). Most of these structures have a ligand bound (e.g. inhibitor or substrate) and/or are protein variants with mutations in substrate-binding residues (Table 3). Amongst both cohorts (Table 1, Table 3) several different space groups have been observed, including P21, C2, P21212, P212121. Amongst the 28 structures referred to in this article (Table 1, Table 3), similar unit cells correspond to each space group.
Table 3

Space groups, unit cells and other information for previously published Mtb-AnPRT structures crystallized in imidazole-malate and PEG4000.

PDB IDRefSolvent contentUnit Cell
Space GroupResolution (Å)ChainsNotesPDB DOI
β (°)A (Å)B (Å)C (Å)

3QS8[2]46%90°7881111P212.00A,B,C,DCo-crystal10.2210/pdb3qs8/pdb
3UU1[2]45%90°7811180P211.82A,B,C,DCo-crystal10.2210/pdb3uu1/pdb
3R6C[2]44%110°9478100C21.83A,BCo-crystal10.2210/pdb3r6c/pdb
4IJ1[5]45%1119578102C21.79A,BCo-crystal10.2210/pdb4ij1/pdb
4X58[6]50%1119578101C21.75A,BMutant10.2210/pdb4x58/pdb
4X59[6]50%1129578102C21.80A,BMutant10.2210/pdb4x59/pdb
4X5A[6]49%1129478102C21.93A,BMutant10.2210/pdb4x5a/pdb
4X5B[6]45%1119478100C22.47A,BMutant10.2210/pdb4x5b/pdb
4X5C[6]49%1119478101C22.33A,BMutant10.2210/pdb4x5c/pdb
4X5E[6]50%1109579101C21.77A,BMutant10.2210/pdb4x5e/pdb
4GIU[5]46%901118179P212121.67A,BCo-crystal10.2210/pdb4giu/pdb
4GKM[5]46%901118178P212121.67A,BCo-crystal10.2210/pdb4gkm/pdb
3QR9[2]57%907992120P2121211.87A,BLigand-free10.2210/pdb3qr9/pdb
4M0R[5]56%907992120P2121211.96A,BCo-crystal10.2210/pdb4m0r/pdb
4N5V[7]57%908093121P2121211.90A,BSoak10.2210/pdb4n5v/pdb
4N8Q[7]56%908091120P2121212.08A,BSoak10.2210/pdb4n8q/pdb
4N93[7]57%908092121P2121212.03A,BSoak10.2210/pdb4n93/pdb
4OWM[7]60%907992121P2121211.99A,BSoak10.2210/pdb4owm/pdb
4OWN[7]60%908092121P2121212.11A,BSoak10.2210/pdb4own/pdb
4OWO[7]60%907992121P2121211.99A,BSoak10.2210/pdb4owo/pdb
4OWQ[7]61%907992122P2121211.89A,BSoak10.2210/pdb4owq/pdb
4OWS[7]60%908092121P2121212.43A,BSoak10.2210/pdb4ows/pdb
4OWU[7]60%907992121P2121211.89A,BSoak10.2210/pdb4owu/pdb
4OWV[7]60%908092120P2121211.90A,BSoak10.2210/pdb4owv/pdb
4X5D[6]60%908092121P2121212.30A,BMutant10.2210/pdb4x5d/pdb
Space groups, unit cells and other information for previously published Mtb-AnPRT structures crystallized in imidazole-malate and PEG4000. P212121 is the most common space group for macromolecular structures, and it has been proposed that this is due to its capacity to accommodate repositioning, i.e. rotations or translations, within the asymmetric unit, without loss of crystal contacts [3]. The structure of wild-type Mtb-AnPRT without ligands (PDB ID: 3QR9) has previously been solved from protein crystallized in imidazole-malate and PEG4000 in the space group P212121, with two monomers (A, B) in the asymmetric unit, a unit cell of 79×92×120 Å, and 57% solvent content [2]. Mtb-AnPRT is a homodimeric protein with an extended “S”-shape, with each subunit containing two domains [4]. In the ligand-free structure, a single dimer (the biological assembly) is found in the asymmetric unit [2]. The two subunits of the dimer are related by a non-crystallographic two-fold symmetry axis (NCS).

Data for protein complexes with inhibitors

The three protein:inhibitor complexes (PDB IDs: 5BO2, 5BO3, 5BNE) were solved in the absence of metals and substrate. For these structures, the solvent content has decreased by ~ 10%, the unit cell has changed (i.e. dimension(s) decreased by 10–20 Å), and the space group has changed to P21 or C2, compared to the ligand-free wild-type structure. In structures of AnPRT from other prokaryote species, domain movement is observed within subunits due to substrate binding and results in compression of the homodimer by 10 Å (e.g. Dmax (maximum distance) changes from 110 to 100 Å [8]). However, superposition of the subunits in the new Mtb-AnPRT structures onto the subunits of the ligand-free structure indicates there are no large changes (Table 4; [9]). Additionally, the longest dimension of the Mtb-AnPRT dimer is relatively unchanged between the ligand-free protein structure and the protein:ligand complex structures (Table 4; [10]). Thus, the changes in space group are not driven by domain movements within each subunit.
Table 4

Comparison Mtb-AnPRT subunits found in the 3 new structures to ligand-free structure.

RMSDa to chain A-3QR9 (Å)RMSDa to chain B-3QR9 (Å)Longest dimension of dimer (Å)
3qr9.pdb:A0.89109
3qr9.pdb:B0.89
5bo2.pdb:A0.670.68110
5bo2.pdb:B0.660.73
5bo3.pdb:A0.630.53110
5bo3.pdb:B0.620.73
5bne.pdb:A0.570.53109
5bne.pdb:B0.460.74
5bne.pdb:C0.460.92109
5bne.pdb:D0.550.60

Root mean standard difference (RMSD) between the Calpha atoms

Comparison Mtb-AnPRT subunits found in the 3 new structures to ligand-free structure. Root mean standard difference (RMSD) between the Calpha atoms The P21 structure (PDB ID: 5BNE) contains an inhibitor annotated as 8k, and is the third structure of Mtb-AnPRT with this space group determined for protein crystallized in the imidazole-malate condition. The increased components in this structure's asymmetric unit (chains A-D, vs. chains A and B; Fig. 1A) means that the lower symmetry described by P21 can generate equivalent protein content in a similarly-sized unit cell as is observed with structures defined by space groups P212121 or P21212. The ß angle of 91° could be taken to suggest that the space group should be orthorhombic (e.g. P21212 or P212121). Both POINTLESS [11] and ZANUDA [12] indicated that P21 was the correct space group for this dataset, however.
Fig. 1

Understanding changes in crystal packing in the Mtb-AnPRT structures with inhibitors. (A) Superposition of the dimer (cartoon) from a Mtb-AnPRT:inhibitor structure defined by space group P21, PDB ID: 5BNE (chain A, B, C and D in green, cyan, pink and yellow, respectively), onto that of the ligand-free Mtb-AnPRT structure (PDB ID: 3QR9 [2]; P212121; chain A and B in dark and light grey, respectively). The figure includes adjacent dimers (ribbons) in equivalent crystal layers (c-b plane in 3QR9 [2] and c-a plane in 5BNE). In (B) the superposition is re-colored with the Mtb-AnPRT:inhibitor structure in yellow and the ligand-free Mtb-AnPRT structure in dark grey. Arrows highlight the reorientation of dimers relative to each other. (C) Superposition of the dimer (cartoon) from a Mtb-AnPRT:inhibitor structure defined by space group C2, PDB ID: 5BO2 (marine blue) onto that of the ligand-free Mtb-AnPRT structure (PDB ID: 3QR9 [2]; P212121; dark grey). In (D) superpositions in panels B-C are combined.

Understanding changes in crystal packing in the Mtb-AnPRT structures with inhibitors. (A) Superposition of the dimer (cartoon) from a Mtb-AnPRT:inhibitor structure defined by space group P21, PDB ID: 5BNE (chain A, B, C and D in green, cyan, pink and yellow, respectively), onto that of the ligand-free Mtb-AnPRT structure (PDB ID: 3QR9 [2]; P212121; chain A and B in dark and light grey, respectively). The figure includes adjacent dimers (ribbons) in equivalent crystal layers (c-b plane in 3QR9 [2] and c-a plane in 5BNE). In (B) the superposition is re-colored with the Mtb-AnPRT:inhibitor structure in yellow and the ligand-free Mtb-AnPRT structure in dark grey. Arrows highlight the reorientation of dimers relative to each other. (C) Superposition of the dimer (cartoon) from a Mtb-AnPRT:inhibitor structure defined by space group C2, PDB ID: 5BO2 (marine blue) onto that of the ligand-free Mtb-AnPRT structure (PDB ID: 3QR9 [2]; P212121; dark grey). In (D) superpositions in panels B-C are combined. (A) Superposition of the dimer (cartoon) from a Mtb-AnPRT:inhibitor structure defined by space group P21, PDB ID: 5BNE (chain A, B, C and D in green, cyan, pink and yellow, respectively), onto that of the ligand-free Mtb-AnPRT structure (PDB ID: 3QR9 [2]; P212121; chain A and B in dark and light grey, respectively). The figure includes adjacent dimers (ribbons) in equivalent crystal layers (c-b plane in 3QR9 [2] and c-a plane in 5BNE). In (B) the superposition is re-colored with the Mtb-AnPRT:inhibitor structure in yellow and the ligand-free Mtb-AnPRT structure in dark grey. Arrows highlight the reorientation of dimers relative to each other. (C) Superposition of the dimer (cartoon) from a Mtb-AnPRT:inhibitor structure defined by space group C2, PDB ID: 5BO2 (marine blue) onto that of the ligand-free Mtb-AnPRT structure (PDB ID: 3QR9 [2]; P212121; dark grey). In (D) superpositions in panels B-C are combined. Structural superposition of the dimers from Mtb-AnPRT:inhibitor structures (PDB ID: 5BNE and 5BO2) onto the dimer present in the P212121 ligand-free Mtb-AnPRT structure (PDB ID: 3QR9 [2]) revealed a reorientation of the protein dimers relative to each other (Fig. 1B and C). The combination of these superpositions (Fig. 1D) indicates that the lattice in the P21 structure corresponds to an intermediate position between the lattice observed for P212121 and C2 structures. We propose the subunits that are related by crystallographic symmetry elements in the P212121 structures are related by pseudosymmetry elements in the P21 structure. Pseudosymmetry occurs where a non-crystallographic symmetry element within the asymmetric unit is close to a crystallographic symmetry operators [13]. Thus, the P21 space group has been correctly assigned, even though the unit cell has a β of approximately 90 °. The generation of the protein: inhibitor structures, involved experiments, with all three inhibitors, using both co-crystallization and soaking-in methods. The structures deposited on the PDB correspond to those where the clearest density was observed for the inhibitor (i.e. modelled with full occupancy; Fig. 2). In Table 5 there are data statistics corresponding to Mtb-AnPRT co-crystallized with inhibitor 8i. In Table 6 are data statistics corresponding to inhibitor 8i soaked into a wild-type ligand-free Mtb-APRT crystal. In both cases, with no manual intervention, the datasets processed in XDS [14] and AIMLESS [11] as space group C2. Thus, in this study, there no correlation was found between space group type and the method by which the ligand was introduced (i.e. soaking vs. co-crystallization).
Fig. 2

Omit and fitted map for inhibitors bound in Mtb-AnPRT structures. The Fo-Fc map calculated (green, contoured at 3 σ) prior to the addition of ligands to the model for A) 8k, B) 8j and C) 8i (PDB entries 5BNE, 5BO3 and 5BO2, respectively). The 2Fo-Fc map calculated (blue, contoured at 1 σ) after final refinement, with model including the ligands for D) 8k (black), E) 8j (green) and F) 8i (pink).

Table 5

Statistics for dataset of Mtb-AnPRT co-crystallized with inhibitor 8i.

Data collection

AnPRT complexed with8i
Space groupC2
Cell dimensions
 a, b, c (Å)94.6, 78.1, 102.8
 β (deg)110.9
Unique reflectionsa387946 (24179)
Resolution range (Å)a48-1.95 (2.00-1.95)
Rmergea0.138 (1.237)
Rp.i.m.a0.054 (0.488)
Mean I/σ(I)a9.9 (1.5)
CC1/2a0.997 (0.679)
Completeness (%)a99.6 (94.0)
Redundancya7.6 (7.1)
Wilson B factor20.5

b The average atomic temperature factor. cRwork=(|Fobs| - |Fcalc|)/|Fobs| and Rfree=∑T (|Fobs| - |Fcalc|)/∑T |Fobs|, where T is a test dataset of 5% of the total reflections randomly chosen and set aside before refinement. d RMSD from ideal geometry values from Engh and Huber (1991)[15].

Outer resolution shell is shown in parentheses.

Table 6

Data and refinement statistics for AnPRT complexes with inhibitors.

Data collection

AnPRT complexed with8i8j8k
PDB code5BO25BO35BNE
Space groupC2C2P21
Cell dimensions
 a, b, c (Å)94.5, 78.0, 102.995.0, 78.1, 102.677.3, 78.4, 117.2
 β (deg)111.0111.190.7
Unique reflectionsa47170 (3415)68993 (3669)75079 (4387)
Resolution range (Å)a47-2.00 (2.05-2.00)48-1.75 (1.78-1.75)47-2.15 (2.19-2.15)
Rmergea0.121 (0.856)0.121 (1.762)0.111 (0.711)
Rp.i.m.a0.076 (0.564)0.046 (0.688)0.073 (0.477)
Mean I/σ(I)a8.5 (1.5)13.3 (1.2)6.9 (1.5)
CC1/2a0.993 (0.564)0.998 (0.465)0.993 (0.502)
Completeness (%)a99.8 (97.7)97.8 (93.7)98.4 (77.3)
Redundancya3.4 (3.3)7.8 (7.4)3.0 (2.9)
Wilson B factor15.116.321.4
Refinement
Atoms, B factor (Å2)b
Protein4788, 25.84746, 24.69280, 29.0
Solvent352, 29.7402, 29.2353, 29.5
Ligands79, 33.266, 26.6107, 30.6
Rwork/Rfree (%/%)a,c0.192/0.2320.206/0.2400.207/0.235
(0.276/0.324)(0.319/0.336)(0.284/0.332)
Ramachandran outliers (%)0.310.160.31
R.m.s.d. of
 Bond lengths (Å)d0.0030.0050.003
 Bond angles (°)d0.7740.8990.745

Outer resolution shell is shown in parentheses.

The average atomic temperature factor.

Rwork=(|Fobs| - |Fcalc|)/|Fobs| and Rfree=∑T (|Fobs| - |Fcalc|)/∑T |Fobs|, where T is a test dataset of 5% of the total reflections randomly chosen and set aside before refinement.

RMSD from ideal geometry values from Engh and Huber[15].

Omit and fitted map for inhibitors bound in Mtb-AnPRT structures. The Fo-Fc map calculated (green, contoured at 3 σ) prior to the addition of ligands to the model for A) 8k, B) 8j and C) 8i (PDB entries 5BNE, 5BO3 and 5BO2, respectively). The 2Fo-Fc map calculated (blue, contoured at 1 σ) after final refinement, with model including the ligands for D) 8k (black), E) 8j (green) and F) 8i (pink). Statistics for dataset of Mtb-AnPRT co-crystallized with inhibitor 8i. b The average atomic temperature factor. cRwork=(|Fobs| - |Fcalc|)/|Fobs| and Rfree=∑T (|Fobs| - |Fcalc|)/∑T |Fobs|, where T is a test dataset of 5% of the total reflections randomly chosen and set aside before refinement. d RMSD from ideal geometry values from Engh and Huber (1991)[15]. Outer resolution shell is shown in parentheses. Data and refinement statistics for AnPRT complexes with inhibitors. Outer resolution shell is shown in parentheses. The average atomic temperature factor. Rwork=(|Fobs| - |Fcalc|)/|Fobs| and Rfree=∑T (|Fobs| - |Fcalc|)/∑T |Fobs|, where T is a test dataset of 5% of the total reflections randomly chosen and set aside before refinement. RMSD from ideal geometry values from Engh and Huber[15].

Experimental design, materials and methods

Materials

Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich, Scharlau, or Pure Science. The purification of Mtb-AnPRT, as well as the synthesis and biochemical characterization of its inhibitors annotated as 8i, 8j and 8k (Table 2), are outlined in the article entitled “Anthranilate phosphoribosyltransferase: Binding determinants for 5′-phospho-alpha- [1].

Crystallization

Crystals of Mtb-AnPRT were obtained in hanging drops of 1–2 μL protein solution (3.0–3.1 mg mL−1 in final storage buffer) with the equivalent amount of reservoir solution in a fine screen of 0.2 M imidazole-malate pH 7.0–8.5, 5–15% polyethylene glycol (PEG) 4000, as previously reported [2]. Complexes were prepared either by co-crystallization or by soaking with ligands (details in Table 2). The crystallization drops were seeded from previously formed crystals of Mtb-AnPRT, by streak seeding using a cat whisker. Data collection occurred within a few days after crystallization. In preparation for data collection, crystals were typically soaked in a reservoir solution containing cryoprotectant 15% PEG4000 and appropriate ligands (details in Table 2), before being flash-cooled in liquid nitrogen.

Data collection, structure solution and refinement

Data were collected at the Australian Synchrotron, Beamlines MX1 and MX2 at 110 K. The crystals of the Mtb-AnPRT complexes diffracted to a maximum resolution that varied between 1.75 and 2.15 Å. X-ray diffraction spots were indexed and integrated with XDS [14] and scaled with AIMLESS [11]. The high resolution cut-off was determined based on a correlation coefficient (CC1/2) [16] exceeding 0.5, with mean I/σ between 1 and 1.5, and a Rp.i.m. of 0.7 or less, as calculated by AIMLESS [11]. Rp.i.m. is defined as ∑hkl [1/(n−1)]×Rmerge, with Rmerge defined as ∑hkl|I(hkl)-|/∑hkl, where is the mean of symmetry-equivalent reflections of I(hkl) [17]. Data and refinement statistics are given in Table 5, Table 6. Mtb-AnPRT (chain A of 3QR9 [2]), without solvent or ligands, and with loops I and II removed, was used as the search model for structure determination by molecular replacement using Phaser [18]. Refinement and model building was performed with COOT [19], Refmac5 [20], and PHENIX [21]. After positioning waters, omit maps were examined (Fig. 2) and ligands placed, with subsequent refinement including restraints for the ligands generated by phenix.elbow [21]. Restraints on protein bond lengths and angles were based on the ideal values of Engh and Huber [15] and model quality was assessed using MolProbity [22]. Figures illustrating structural details were prepared using PyMOL. The Fo-Fc map calculated (green, contoured at 3 σ) prior to the addition of ligands to the model for A) 8k, B) 8j and C) 8i (PDB entries 5BNE, 5BO3 and 5BO2, respectively). The 2Fo-Fc map calculated (blue, contoured at 1 σ) after final refinement, with model including the ligands for D) 8k (black), E) 8j (green) and F) 8i (pink).
Subject areaProteomics and Biochemistry
More specific subject areaStructural biology
Type of dataTables, figures and X-ray diffraction images
How data was acquiredX-ray macromolecular crystallography;
Australian Synchrotron MX1 and MX2 beamlines
Data formatUnprocessed, processed, deposited with crystal packing analyzed.
Experimental factorsProtein crystals soaked and co-crystallized with ligands
Experimental featuresContrast of the different protein crystal packing associated with different inhibitors and/or introduced by soaking or co-crystallization.
X-ray diffraction datasets for co-crystallization and soaked-in experiments with the same inhibitor indicate space group changes are independent of method used to introduce the inhibitor.
Data source locationData collected in Melbourne, Australia.
Data accessibilityThe atomic coordinates and observed structure factors are available from Protein Data Bank with accession numbers:5BO2,5BO3and5BNE.
The X-ray diffraction image files corresponding to datasets from two experiments are hosted by Mendeley:
http://dx.doi.org/10.17632/2zrfgv34nb.1
http://dx.doi.org/10.17632/xgn5z8jnr7.1
Related research articleAnthranilate phosphoribosyltransferase: Binding determinants for 5′-phospho-alpha-d-ribosyl-1′-pyrophosphate (PRPP) and the implications for inhibitor design “in press”.
https://doi.org/10.1016/j.bbapap.2017.08.018
  20 in total

1.  Refinement of macromolecular structures by the maximum-likelihood method.

Authors:  G N Murshudov; A A Vagin; E J Dodson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1997-05-01

2.  Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions.

Authors:  E Krissinel; K Henrick
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

3.  Linking crystallographic model and data quality.

Authors:  P Andrew Karplus; Kay Diederichs
Journal:  Science       Date:  2012-05-25       Impact factor: 47.728

4.  Structures of Mycobacterium tuberculosis Anthranilate Phosphoribosyltransferase Variants Reveal the Conformational Changes That Facilitate Delivery of the Substrate to the Active Site.

Authors:  Tammie V M Cookson; Genevieve L Evans; Alina Castell; Edward N Baker; J Shaun Lott; Emily J Parker
Journal:  Biochemistry       Date:  2015-10-06       Impact factor: 3.162

5.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

6.  Repurposing the chemical scaffold of the anti-arthritic drug Lobenzarit to target tryptophan biosynthesis in Mycobacterium tuberculosis.

Authors:  Genevieve L Evans; Swarna A Gamage; Esther M M Bulloch; Edward N Baker; William A Denny; J Shaun Lott
Journal:  Chembiochem       Date:  2014-03-12       Impact factor: 3.164

7.  An introduction to data reduction: space-group determination, scaling and intensity statistics.

Authors:  Philip R Evans
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

8.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

9.  Surprises and pitfalls arising from (pseudo)symmetry.

Authors:  Peter H Zwart; Ralf W Grosse-Kunstleve; Andrey A Lebedev; Garib N Murshudov; Paul D Adams
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2007-12-05

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.